Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

Siena, S; Sartore-Bianchi, A; Personeni, N; Pietrantonio, F; Germano, G; Amatu, A; Bonoldi, E; Valtorta, E; Barault, L; Di Nicolantonio, F; Siravegna, G; Crisafulli, G; Rimassa, L; De Braud, FG; Santoro, A; Lazzari, L; Luraghi, P; Amirouchene-Angeloz

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索